Xconomy National

Archives

by in
Entry Author Date Location
George Scangos, the Boy From Working Class Boston, on His Road Back to Lead Biogen Idec Luke Timmerman 08/31/11 Boston
Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent Luke Timmerman 07/18/11 National
Dendreon Faces Internet-Fueled Shareholder Uprising, Led by a Little Guy in Kansas Luke Timmerman 04/01/11 Seattle
Biogen Idec Nabs Doug Williams as R&D Head, Steve Holtzman as BD Chief To Fill Out Management Team Luke Timmerman 01/05/11 Boston
Biogen Idec Chief Aims to Make Firm More Like Biotech and Less Like Pharma with Restructuring Plan Ryan McBride 11/04/10 Boston
5 Biotech Storylines to Watch in Boston Ryan McBride 10/13/10 Boston
Motricity’s Ryan Wuerch on the Post-IPO Game Plan, International Expansion, and the New Wave of Mobile Thea Chard 10/08/10 Seattle
Genzyme Boss Henri Termeer Not Ready To Sell to Sanofi, Ride Into the Sunset, Sources Say Ryan McBride 09/22/10 Boston
Genzyme Agrees to Sell Genetics Unit to LabCorp for $925M Ryan McBride 09/13/10 Boston
Susan Windham-Bannister on the State of the State’s $1B Life Sciences Initiative, Part II Ryan McBride 08/18/10 Boston
Susan Windham-Bannister on the State of the State’s $1B Life Sciences Initiative, Part I Ryan McBride 08/17/10 Boston
Xconomy Readers Set $20B Pricetag on Genzyme—Is That Too Rich for Sanofi-Aventis? Ryan McBride 07/29/10 Boston
Genzyme Stock Surges 15 Percent on Sanofi Buyout Speculation Luke Timmerman 07/23/10 Boston
New CEO George Scangos Says Biogen Idec’s R&D Has to Improve Ryan McBride 07/01/10 Boston
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO Ryan McBride 06/30/10 Boston
Motricity Completes IPO, Settles For $50M Luke Timmerman 06/18/10 Seattle
Curis Misses Mark in Cancer Drug Trial, Genzyme Re-Elects Full Board, GTC Cuts Jobs, & More Boston-Area Life Sciences News Erin Kutz 06/18/10 Boston
Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Ryan McBride 06/16/10 Boston
Polaris Raises $234M for New Fund, BioScale Pins Down $25M, Clinical Data Nets $30M, & More Boston-Area Deals News Erin Kutz 06/16/10 Boston
Genzyme Borrows $1B for Stock Buyback Ryan McBride 06/15/10 Boston
Modumetal Closes Series B, TerraPower Pulls In $35M, Vertafore Bought for $1.4B, & More Seattle-Area Deals News Gregory T. Huang 06/15/10 Seattle
Motricity, Riding the Mobile Software Wave, Primed for $85M IPO This Week Luke Timmerman 06/14/10 Seattle
Biogen CEO Retires, Genzyme Board Nominates Amgen Vet and Strikes Deal with Icahn, Xconomy Spotlights Life Sciences XSITE Speakers, & More Boston-Area Life Sciences News Erin Kutz 06/11/10 Boston
Genzyme Cuts Deal With Carl Icahn on Eve of Shareholder Vote Ryan McBride 06/09/10 Boston
Biogen’s CEO Retires Tomorrow, COO to Follow Ryan McBride 06/07/10 Boston
Genzyme Taps Amgen Vet for Board Ryan McBride 06/07/10 Boston
Oxford’s Fambrough Leaves for Dicerna, Clinical Data Aims to Take on Big Pharma with Antidepressants, Genzyme’s Termeer Courts Shareholders, & More Boston-Area Life Sciences News Erin Kutz 05/14/10 Boston
Genzyme in “Tough Spot” with Icahn Proxy Challenge—CEO Termeer Courting Key Shareholders Ryan McBride 05/13/10 Boston
Icahn Blasts Genzyme Manufacturing, Glaxo Halts “Red Wine” Drug Trial, Ariad Gets $69M from Merck, & More Boston-Area Life Sciences News Erin Kutz 05/07/10 Boston
$2B Stock Buyback for Genzyme Erin Kutz 05/06/10 Boston
Page 1 of 6 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.